All Cellarity articles
-
ArticleAI steps into drug safety: predicting liver injury earlier than ever before
Drug-induced liver injury remains one of drug development’s most costly pitfalls. Now, AI and transcriptomics may offer a way to spot risks long before they reach patients.
-
NewsHow AI and cell data combine to make drug discovery faster
Cellarity has published a new paper in detailing an AI-powered framework that integrates single-cell transcriptomics to make drug discovery faster and more successful.
-
ArticleChanging the paradigm of drug discovery processes with AI
We had the privilege of speaking to Cellarity’s CEO, Fabrice Chouraqui, about how the company is leveraging AI to completely revolutionise the drug discovery process and unlock treatments for a vast array of diseases, even in the absence of known targets.
-
ArticleThe power of single-cell technologies
Drug Target Review’s Taylor Mixides interviews Cellarity's CEO Fabrice Chouraqui about applying Artificial Intelligence (AI) and Machine Learning (ML) to evolving single-cell technologies.
-
ArticleDrug Target Review Screening eBook 2023
In this eBook, uncover the transformative potential of AI/ML in single-cell technologies and gain insights into disease progression.